Deloitte Haskins & Sells

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru – 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

 We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of SEQUENT SCIENTIFIC LIMITED ("the Company"), for the quarter and nine months ended December 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**

Chartered Accountants (Firm's Registration No. 008072S)

Sathya P. Koushik

Partner

(Membership No. 206920)

Thane, February 01, 2019 SPK/JKS/DSS/2019



STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2018

(Rs. in Lakhs)

Revenue from operations (Refer note 3) 4,944,20 5,054,20 1,068,20 1								(Rs. in Lakhs)
Revenue from operations (Refer note 3)		Particulars	ended 31-Dec-2018	months ended 30-Sep 2018	months ended in previous period 31-Dec-2017	figures for current period ended 31-Dec-2018	figures for previous period ended 31-Dec-2017	31-Mar-18
In December income 1911 1917	_	Payanua from aparations (Pafor note 2)						10,723.60
Total income (HI)		, ,						
N Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Cost of materials consumed (c) Cost of materials consumed (c) Contanges in inventriors of finished goods, work-in-progress and stock-in-trade (c) Changes in inventriors of finished goods, work-in-progress and stock-in-trade (c) Changes in inventriors of finished goods, work-in-progress and stock-in-trade (c) Changes in inventriors of finished goods, work-in-progress and stock-in-trade (c) Changes in inventriors of finished goods, work-in-progress and stock-in-trade (c) Changes in inventriors of finished goods, work-in-progress and stock-in-trade (c) Changes in inventriors of finished goods, work-in-progress and stock-in-trade (c) Changes in inventriors of finished goods, work-in-progress and stock-in-trade (d) Contanges on sale of goods (d) Contanges on sale of goods (d) Contanges (d)								
(a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventriets of finished goods, work-in-progress and stock-in-trade (d) Expanses of Stock of the Stock of Stock	Ш	Total income (I+II)	5,116.40	4,081.00	3,120.74	12,261.50	9,961.60	13,150.50
(a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventricits of finished goods, work-in-progress and stock-in-trade (d) Excise duty on sale of goods (e) Changes in inventricits of finished goods, work-in-progress and stock-in-trade (d) Excise duty on sale of goods (e) Commertion and processing charges (f) Excise duty on sale of goods (e) Commertion and processing charges (f) Excise duty on sale of goods (e) Commertion and processing charges (f) Excise duty on sale of goods (e) Commertion and processing charges (f) Excise duty on sale of goods (e) Commertion and processing charges (f) Excise duty on sale of goods (f) Commertion and processing charges (g) Finance course amortisation expense (g) Finance course amortisation expense (g) Commertion (g) Finance course (g) Commertion (g) F								
Dispurissaes of stock-in-trade (c) Changes in inventions of finished goods, work-in-progress and stock-in-trade (c) Changes in inventions of finished goods, work-in-progress and stock-in-trade (c) Changes in inventions of finished goods, work-in-progress and stock-in-trade (c) Changes in inventions of finished goods, work-in-progress and stock-in-trade (c) Excise duty on sale of goods (c) Ex	IV	Expenses						
Dispurchases of stock-in-trade (c) Changes in inventions of finished goods, work-in-progress and stock-in-trade (c) Changes in inventions of finished goods, work-in-progress and stock-in-trade (d) Excise duty on sale of goods (e) Cornersion and processing charges 979.80 912.30 414.20 229.01 77.70 117.70		(a) Cost of materials consumed	2,331.20	2,239.20	368.65	5,486.50	1,963.50	3,065.70
Col Changes in Inventories of finished goods, work-in-progress and slock-in-trade (i) Excise duty on sale of goods (ii) Colored and processing charges 979.80 912.30 414.20 2.299.10 787.72 112.75					1 346 10	1.827.50	3.966.20	4,914.30
Second S			221.00	0,0.00	1,010.10		5,555.25	
(c) Excise duty on sale of goods		, ,	3.40	(937.30)	(144.80)	(1,094.70)	(7.10)	(42.20)
Oncomession and processing charges 979.80 912.30 414.20 2.290.10 757.72 1.175.75 1.175.10 1.195.10 1.							122.00	122.00
(i) Employee benefits expense (g) Finance cots (g) Financ		, ,				0.000.40		
Commence costs 131.90		(e) Conversion and processing charges						
(ii) Depreciation and amortisation expense 229.70 178.50 59.14 405.90 252.30 386. (i) Other expenses 5.029.80 3.899.70 2.950.31 11,641.70 9,724.90 12,988. 7 total expenses 5.029.80 3.899.70 2.950.31 11,641.70 9,724.90 12,988. 7 total expenses 5.029.80 3.899.70 2.950.31 11,641.70 9,724.90 12,988. 7 total expenses 7 total expenses 5.029.80 3.899.70 2.950.31 11,641.70 9,724.90 12,988. 7 total expenses 7 total expense 7 total expense 7 total expenses 7 total expense 7 total expen		(f) Employee benefits expense	324.60	262.00	239.61	744.10	1,002.50	1,185.00
(iii) Depreciation and amordisation expense () Other expenses Sor. 30 569.80 (0.50 17.52 0) 11.52.9 (0.50.53.78 2.14.00) Other expenses 5.029.80 3,809.70 2,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 11,641.70 9,724.90 12,958.70 12,950.31 12,950.32 12,958.70 12,950.32 12,950.31 12,950.32 12,950.31 12,950.32 12,950.		(g) Finance costs	131.90	6.20	6.41	139.40	31.10	39.20
(i) Other expenses 807.30 559.80 625.00 1,752.00 1,633.78 2,140.		,,	229.70	178.50	95.14	495.90	252.30	366.70
Total expenses 5,029.80 3,899.70 2,950.31 11,641.70 9,724.90 12,988.						1 752 90	1 635 78	2,140.90
V Profit/(loss) from continuing operations before tax and exceptional items (ill-IV) Exceptional items (ill-IV) Exceptional items (ill-IV) Exceptional items (ill-IV) Profit/(loss) from continuing operations before tax (V-VI) 86.60 271.30 170.43 619.80 236.70 66.								
V Exceptional items (III-IV) Secoptional items (III-IV) Secoptional items (III-IV) Exceptional items (III-IV) Secoptional items (III-IV) Secoptiona		Total expenses	5,029.60	3,009.70	2,950.51	11,641.70	3,724.30	12,300.10
Profit(loss) from continuing operations before tax (V-VI) 86.60 271.30 170.43 619.80 236.70 66.	٧		86.60	271.30	170.43	619.80	236.70	182.40
VIII Tax expense (a) Current tax (b) MAT credit entitlement (c) MAT credit entitlement written off - -	VI	Exceptional items loss / (gain) (net) (Refer note 5)	-	-	-	-	-	116.10
(a) Current tax (b) MAT credit entitlement (c) MAT credit entitlement written off Total tax expenses (c) MAT credit entitlement written off Total tax expenses (d) MAT credit entitlement written off Total tax expenses (e) MAT credit entitlement written off Total tax expenses (e) MAT credit entitlement written off Total tax expenses (e) MAT credit entitlement written off Total tax expenses (e) MAT credit entitlement written off Total tax expenses (e) MAT credit entitlement operations (e) Urrent tax (f) MAT credit entitlement operations (g) Urrent tax (g) MAT credit entitlement operations (g) Urrent tax (g) MAT credit entitlement operations (g) MAT credit entitlement operations after tax (g) MAT credit entitlement operations (g) MAT credit e	VII	Profit/(loss) from continuing operations before tax (V-VI)	86.60	271.30	170.43	619.80	236.70	66.30
(a) Current tax (b) MAT credit entitlement (c) MAT credit entitlement written off Total tax expenses IX Profit/(loss) from Continuing operations after tax (VII-VIII) Refit/(loss) from discontinued operations Gain on demerger of Human API business (Refer note 7) Tax expense of discontinued operations (a) Current tax (b) MAT credit entitlement written off Total tax expenses Tax expenses Profit/(loss) from discontinued operations Gain on demerger of Human API business (Refer note 7) Tax expense of discontinued operations (a) Current tax (b) MAT credit entitlement Profit/(loss) from discontinued operations (a) Current tax (b) MAT credit entitlement Profit/(loss) from discontinued operations (a) Current tax (b) MAT credit entitlement Profit/(loss) for the period (IX+X) Refit/(loss) for investment in equity instruments (net) Total other comprehensive income for the period Profit/(loss) for investment in equity instruments (net) Total other comprehensive income for the period Profit/(loss) for investment in equity instruments (net) Total other comprehensive income for the period Profit/(loss) for investment in equity instruments (net) Total other comprehensive income for the period Profit/(loss) for investment in equity instruments (not-annualised) For continuing operations (1) Basic (in Rs.) (1) Basic (in Rs.) (2) Diluted (in Rs.) (3) Cup Continued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) (3) Cup Continued operations (4) Basic (in Rs.) (5) Cup Continuing and discontinued operations (6) Basic (in Rs.) (7) Cup Continuing and discontinued operations (8) Basic (in Rs.) (9) Cup Continuing and discontinued operations (1) Basic (in Rs.) (1) Basic (in Rs.) (1) Cup Continuing Apidesontinued operations (1) Basic (in Rs.) (1) Cup Continuing Apidesontinued operations (1) Basic (in Rs.) (1) Cup Continuing Apidesontinued operations (1) Bas	VIII	Tax expense						
Digital Continues Digi	v	•	10.20	50.00	52.15	122.00	52.15	3.87
Column C					600000000000000000000000000000000000000		S (2010) (2010)	
Total tax expenses 52.15 - 52.15 286. IX Profit/(loss) from continuing operations after tax (VII-VIII) 86.60 271.30 118.28 619.80 184.55 (220. X Profit/(loss) from discontinued operations Gain on demerger of Human API business (Refer note 7) 1,707.40 1,707. Gain on demerger of Human API business (Refer note 7)			(19.30)	(58.00)	-	(132.90)	-	(3.87)
X Profit/(loss) from continuing operations after tax (VII-VIII) 86.60 271.30 118.28 619.80 184.55 (220)		(c) MAT credit entitlement written off	-	-	-	-	-	286.67
X Profit/(loss) from discontinued operations Gain on demerger of Human API business (Refer note 7) Tax expense of discontinued operations (a) Current tax (b) MAT credit entitlement Profit/(loss) for miscontinued operations after tax X Profit/(loss) for the period (IX+X) XI I Other comprehensive income liters that will not be reclassified to profit or loss (a) Re-measurements gain / (loss) on defined benefits plans (b) Fair value gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period XI I Total comprehensive income for the period (XI+XII) Year of discontinued operations (1) Basic (in Rs.) Year of discontinued operations (1) Basic (in Rs.) Year of discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of continuing and discontinued operations (1) Basic (in Rs.) Year of		Total tax expenses	-	-	52.15	-	52.15	286.67
X Profit/(loss) from discontinued operations Gain on demerger of Human API business (Refer note 7) Tax expense of discontinued operations (a) Current tax (b) MAT credit entitlement Profit/(loss) from discontinued operations after tax X Profit/(loss) from discontinued operations after tax X Profit/(loss) for the period (IX+X) XI I Other comprehensive income litems that will not be reclassified to profit or loss (a) Re-measurements gain / (loss) on defined benefits plans (b) Fair value gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period XI I Total comprehensive income for the period XI I Total comprehensive income for the period XI I Total comprehensive income for the period (XI+XII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income for the period (XI+XIII) XI I Total comprehensive income								
Gain on demerger of Human API business (Refer note 7) Tax expense of discontinued operations (a) Current tax (b) MAT credit entitlement 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 362.73 - 1,344.67 - 40,861 XI Profit/(loss) for the period (IX+X) XII Other comprehensive income letems that will not be reclassified to profit or loss (a) Re-measurements gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period XIII Total comprehensive income for the period YIII Total comprehensive income for the period (XI+XII) YIII Total comprehensive income for the period (XI+XIII) YIII Total comprehen	IX	Profit/(loss) from continuing operations after tax (VII-VIII)	86.60	271.30	118.28	619.80	184.55	(220.37)
Gain on demerger of Human API business (Refer note 7) Tax expense of discontinued operations (a) Current tax (b) MAT credit entitlement	X	Profit/(loss) from discontinued operations	-	-	-	-	1,707.40	1,707.40
Tax expense of discontinued operations (a) Current tax (b) MAT credit entitlement		10 C C C C C C C C C C C C C C C C C C C	_	-	-	_	-	39,153.70
(a) Current tax			_					
(b) MAT credit entitlement Profit/(loss) from discontinued operations after tax					262.72		262.72	362.73
Profit/(loss) from discontinued operations after tax Profit/(loss) from discontinued operations after tax Profit/(loss) for the period (IX+X) 86.60 271.30 (244.45) 619.80 1,529.22 40,640 XII Other comprehensive income Items that will not be reclassified to profit or loss (a) Re-measurements gain / (loss) on defined benefits plans (b) Fair value gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period 911.30 1,608.50 (2,062.80) (5,192.10) (9,096.40) (14,195 Total other comprehensive income for the period 913.00 1,620.90 (2,069.72) (5,187.00) (9,096.40) (14,232 XIII Total comprehensive income for the period (XI+XII) 999.60 1,892.20 (2,314.17) (4,567.20) (7,570.42) 26,408 Continuing operations (1) Basic (in Rs.) (2) Diluted (in Rs.) (0.15) - 0.55 16 (2) Diluted (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) (0.15) - 0.55 16 (3) Diluted (in Rs.) (0.15) - 0.55 16 (3) Diluted (in Rs.) (0.15) - 0.55 16 (4) Diluted (in Rs.) (0.15) - 0.55 16 (5) Diluted (in Rs.) (0.15) - 0.55 16 (6) Diluted (in Rs.) (0.15) - 0.55 16 (7) Diluted (in Rs.) (0.15) - 0.55 16 (9) Diluted (in Rs.) (0.15) - 0.55 16 (1) Diluted (in Rs.) (0.15) - 0.55			-	-	302.73	1	362.73	- Common
XII Profit/(loss) for the period (IX+X)			-	-	-	7690		
XII Other comprehensive income Items that will not be reclassified to profit or loss (a) Re-measurements gain / (loss) on defined benefits plans (b) Fair value gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period 913.00 1,620.90 (2,069.72) (5,187.00) (9,096.40) (14,195 (14,232 (2,314.17)) (2,314.17) (4,567.20) (7,570.42) 26,408 (14,232 (2,314.17)) (1,567.20) (2,314.17) (4,567.20) (7,570.42) 26,408 (3,14,232 (2,314.17)) (1,567.20) (2,314.17) (4,567.20) (7,570.42) (2,314.17) (1,567.20) (2,314.17) (1,567.20) (2,314.17) (1,567.20) (3,24) (3,314.19) (Profit/(loss) from discontinued operations after tax	-	-	(362.73)	-	1,344.67	40,861.10
Items that will not be reclassified to profit or loss (a) Re-measurements gain / (loss) on defined benefits plans (b) Fair value gain / (loss) from investment in equity instruments (net)	ΧI	Profit/(loss) for the period (IX+X)	86.60	271.30	(244.45)	619.80	1,529.22	40,640.73
(a) Re-measurements gain / (loss) on defined benefits plans (b) Fair value gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period Total comprehensive income for the period (XI+XII) Earnings per equity share: (Face value of Rs. 2 each) (not-annualised) - for continuing operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - or of discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continuing and discontinued operations (1) Basic (in Rs.) - or continui	XII							
(b) Fair value gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period XIII Total comprehensive income for the period (XI+XII) Earnings per equity share: (Face value of Rs. 2 each) (not-annualised) - for continuing operations (1) Basic (in Rs.) - for discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.)		1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	•					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
(b) Fair value gain / (loss) from investment in equity instruments (net) Total other comprehensive income for the period XIII Total comprehensive income for the period (XI+XII) Earnings per equity share: (Face value of Rs. 2 each) (not-annualised) - for continuing operations (1) Basic (in Rs.) - for discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.)		(a) Re-measurements gain / (loss) on defined benefits plans	1.70	12.40	(6.92)	5.10	(3.24)	(37.30)
(net) Total other comprehensive income for the period Still Total comprehensive income for the period (XI+XII) Earnings per equity share: (Face value of Rs. 2 each) (not-annualised) - for continuing operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - for continuing and discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - O.04 - for continuing and discontinued operations (1) Basic (in Rs.) - O.05 - for continuing and discontinued operations (1) Basic (in Rs.) - O.04 - O.11 - O.05 - O.55 - O.63 - O.64 - O.11 - O.05 - O.25 - O.65 - O.63 - O.63 - O.63 - O.63 - O.64 - O.11 - O.65 - O.6								S S
Total other comprehensive income for the period 913.00 1,620.90 (2,069.72) (5,187.00) (9,099.64) (14,232 XIII Total comprehensive income for the period (XI+XII) 999.60 1,892.20 (2,314.17) (4,567.20) (7,570.42) 26,408 Earnings per equity share: (Face value of Rs. 2 each) (not-annualised) - for continuing operations (1) Basic (in Rs.) 0.04 0.11 0.05 0.26 0.08 (0 - for discontinued operations (1) Basic (in Rs.) (0.15) - 0.55 16 (2) Diluted (in Rs.) (0.15) - 0.55 16 (2) Diluted (in Rs.) (0.15) - 0.55 16 (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.26 0.63 16 (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.25 0.63 16 (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.25 0.63 16			911.30	1,608.50	(2,062.80)	(5,192.10)	(9,096.40)	(14,195.40)
Earnings per equity share: (Face value of Rs. 2 each) (not-annualised) - for continuing operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - for discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - (0.15) - (0.15) - (0.55) 16 (2) Diluted (in Rs.) - (0.15) - (0.15) - (0.55) 16 - for continuing and discontinued operations (1) Basic (in Rs.) (1) Basic (in Rs.) (2) Diluted (in Rs.) (3) 0.04 (4) 0.11 (5) 0.10 (6) 0.26 (6) 0.63 (7) 0.63 (8) 0.04 (9) 0.11 (9) 0.26 (9) 0.63 (10) 0.25 (10) 0.26 (10		Li Z	913.00	1,620.90	(2,069.72)	(5,187.00)	(9,099.64)	(14,232.70)
(not-annualised) - for continuing operations (1) Basic (in Rs.) (2) Diluted (in Rs.) - for discontinued operations (1) Basic (in Rs.) - for discontinued operations (1) Basic (in Rs.) - (2) Diluted (in Rs.) - (0.15) - (XIII	Total comprehensive income for the period (XI+XII)	999.60	1,892.20	(2,314.17)	(4,567.20)	(7,570.42)	26,408.03
(1) Basic (in Rs.) (2) Diluted (in Rs.) - for discontinued operations (1) Basic (in Rs.) - 2		(not-annualised)						
(2) Diluted (in Rs.) - for discontinued operations (1) Basic (in Rs.) - (2) Diluted (in Rs.) - (3) Diluted (in Rs.) - (4) Diluted (in Rs.) - (5) Diluted (in Rs.)								
(2) Diluted (in Rs.) - for discontinued operations (1) Basic (in Rs.) - (2) Diluted (in Rs.) - (2) Diluted (in Rs.) - (3) Diluted (in Rs.) - (4) Diluted (in Rs.) - (5) Diluted (in Rs.) - (6) Diluted (in Rs.) - (7) Diluted (in Rs.) - (8) Diluted (in Rs.)		(1) Basic (in Rs.)	0.04	0.11	0.05	0.26	0.08	(0.09)
- for discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) (0.15) - (0.15)		(2) Diluted (in Rs.)	0.04	1	1	1		(0.09)
(1) Basic (in Rs.) (0.15) - 0.55 16 (2) Diluted (in Rs.) (0.15) - 0.55 16 - for continuing and discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.26 0.63 16 (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.25 0.63 16			1			0.20		(5.50)
(1) Basic (in Rs.) (0.15) - 0.55 16 (2) Diluted (in Rs.) (0.15) - 0.55 16 - for continuing and discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.26 0.63 16 (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.25 0.63 16		- for discontinued operations		1				
(2) Diluted (in Rs.) (0.15) - for continuing and discontinued operations (1) Basic (in Rs.) (2) Diluted (in Rs.) (0.15) - 0.55 16 0.04 0.11 0.10 0.26 0.63 16 0.04 0.11 0.10 0.25		La contrata de la contrata del contrata de la contrata del contrata de la contrata del contrata de la contrata del contrata de la contrata del contrata del contrata de la contrata de la contrata del co	2,000	2000	10.45		0.55	10.00
- for continuing and discontinued operations (1) Basic (in Rs.) 0.04 0.11 (0.10) 0.26 0.63 16 (2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.25			-	_	1000000			16.86
(1) Basic (in Rs.) (2) Diluted (in Rs.) 0.04 0.11 0.10 0.26 0.63 16 0.04 0.11 0.10) 0.25 0.63		(2) Diluted (in Ks.)	-	-	(0.15)	-	0.55	16.75
(1) Basic (in Rs.) (2) Diluted (in Rs.) 0.04 0.11 0.10 0.26 0.63 16 0.04 0.11 0.10) 0.25 0.63				1	1		1	
(1) Basic (in Rs.) (2) Diluted (in Rs.) 0.04 0.11 0.10 0.10 0.26 0.63 16 0.04 0.11 0.10) 0.25 0.63		- for continuing and discontinued operations	37			1		
(2) Diluted (in Rs.) 0.04 0.11 (0.10) 0.25 0.63 16			0.04	0.11	(0.10)	0.26	0.63	16.77
			1		1			16.66
See accompanying notes to financial results		(III 110.)	0.04	0.11	(0.10)	0.25	0.63	10.00
The second secon		See accompanying notes to financial results						





Notes:

- 1 The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 01 February 2019. The statutory auditors have carried limited review of the above results.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty upto 30 June 2017. Accordingly, revenue from operations for the nine months ended 31 December 2018 are not comparable with those of the previous periods presented.
- 4 With effect from 01 August 2018, the Company has acquired the EU-GMP API facility at Mahad, Maharashtra for a consideration of Rs. 4,640 lakhs. The Company is in the process of completing the Purchase Price Allocations of this acquisition and the business combination has been accounted based on provisional amounts as permitted under the Indian Accounting Standard 103 "Business Combinations".
- 5 Exceptional items for the year ended 31 March 2018 comprises write-off of ineligible GST credits.
- 6 Tax expenses has been accrued during the current quarter and nine months ended based on estimated Minimum Alternate Tax applicable to the entity and for previous periods, tax expenses are split between continuing and discontinued operations based on book profits from the respective operations.
- 7 Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018, with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited.

In line with the approved Scheme, the comparative information in these results for the quarter and nine months ended 31 December 2017 have been revised from the published financial results for that quarter to exclude the result of the Human API business.

(Rs. in Lakhs)

Particulars	3 months ended	Preceding 3	Corresponding 3 months ended in previous period	Year to date figures for current period ended	Year to date figures for previous period ended	Previous year ended
	31-Dec-2018	30-Sep 2018	31-Dec-2017	31-Dec-2018	31-Dec-2017	31-Mar-18
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income	-	-		-	16,795.60	16,795.60
Total expenses	-	-		-	15,088.20	15,088.20
Profit before exceptional items and tax	-	-	-	-	1,707.40	1,707.40
Exceptional items	-	-	-	-	-	-
Profit/(loss) before tax		-	-	-	1,707.40	1,707.40
Gain on demerger of Human API business	-	-	-	-	-	39,153.70
Tax expenses	-	-	362.73	-	362.73	-
Profit/(loss) for the period	-	-	(362.73)	-	1,344.67	40,861.10
			1		T T	

- 8 'Ind AS 115- Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- 9 The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

Manish Gupta

Managing Director

Place: Thane

Date: 01 February 2019

Deloitte Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru – 560 001
Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

 We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2018 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3. The Statement includes the results of the following entities:
 - i) Alivira Animal Health Australia Pty Ltd;
 - ii) Alivira Animal Health Limited, Ireland;
 - iii) Alivira Animal Health Limited, India;
 - iv) Alivira Saude Animal Brasil Participacoes Ltda;
 - v) Alivira UA Limited;
 - vi) Alivira France;
 - vii) Bremer Pharma GMBH;
 - viii) Comercial Vila Veterinaria de Lleida S.L;
 - ix) Elysian Life Sciences Private Limited;
 - x) Fendigo BV;
 - xi) Fendigo SA;
 - xii) Interchange Veterinária Indústria E Comércio Ltda;
 - xiii) Laboratorios Karizoo, S.A;
 - xiv) Laboratorios Karizoo, S.A. De C.V. (Mexico);
 - xv) N-Vet AB;
 - xvi) Phytotherapic Solutions S.L;
 - xvii) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
 - xviii) SeQuent Antibiotics Private Limited;
 - xix) SeQuent Pharmaceuticals Private Limited;



Deloitte Haskins & Sells

xx) SeQuent Research Limited;

xxi) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S;

xxii) Vila Viña Participacions S.L.

- 4. Based on our review conducted as stated above and based on the consideration of the review reports of other auditors referred to in paragraph 5 below, and except for the possible effects of the matters described in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. We did not review the interim financial results of twelve subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.16,332.85 lakhs and Rs.49,332.63 lakhs for the quarter and nine months ended December 31, 2018, respectively, and total profit after tax of Rs.1,029.45 lakhs and Rs.1,948.30 lakhs and total comprehensive income of Rs.1,029.45 lakhs and Rs.1,948.30 lakhs for the quarter and nine months ended December 31, 2018, respectively, as considered in the consolidated unaudited financial results.

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

6. The consolidated unaudited financial results includes the interim financial results of nine subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue Rs.410.43 lakhs and Rs.1,304.93 lakhs for the quarter and nine months ended December 31, 2018, respectively, and total loss after tax of Rs.140.20 lakhs and Rs.1,209.67 lakhs and total comprehensive loss of Rs.135.60 lakhs and Rs.1,205.07 lakhs for the quarter and nine months ended December 31, 2018, respectively, as considered in the consolidated unaudited financial results.

For **DELOITTE HASKINS & SELLS**

Chartered Accountants (Firm's Registration No. 008072S)

Sathya P. Koushik

Partner

(Membership No. 206920)

Thane, February 01, 2019 SPK/JKS/DSS/2019



STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2018

(Rs. in Lakhs)

_	(Rs. in Lakhs)						
	Particulars	3 months ended 31-Dec-2018	Preceding 3 months ended 30-Sep-2018	Corresponding 3 months ended in the previous year 31-Dec-2017	Year to date figures for the current period ended 31-Dec-2018	Year to date figures for the previous period ended 31-Dec-2017	Previous year ended 31-Mar-2018
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Revenue from operations (Refer note 5)	27,052.80	25,172.40	22,491.69	75,740.40	61,668.94	84,944.80
Н	Other income	198.80	244.30	343.80	624.50	1,366.24	1,658.10
Ш	Total income (I+II)	27,251.60	25,416.70	22,835.49	76,364.90	63,035.18	86,602.90
IV	Expenses						
	(a) Cost of materials consumed	9,872.50	9,785.00	8,845.38	30,165.10	23,752.48	34,459.40
	(b) Purchase of stock-in-trade	3,313.90	3,457.60	4,622.06	10,126.20	10,952.68	14,184.10
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	938.90	(136.30)	(1,454.24)	(408.60)	(804.24)	(2,394.30)
	(d) Excise duty on sale of goods	-	-	-	-	161.02	161.02
	(e) Employee benefits expense	3,688.20	3,446.10	3,001.41	10,647.90	8,489.03	11,382.80
	(f) Finance costs	834.50	777.20	987.33	2,390.00	2,339.34	3,306.90
	(g) Depreciation and amortisation expense	1,115.80	1,020.20	1,172.70	3,099.80	3,186.23	4,134.30
	(h) Other expenses	5,670.80	5,846.60	5,600.96	16,616.30	13,844.93	18,853.80
	Total expenses	25,434.60	24,196.40	22,775.60	72,636.70	61,921.47	84,088.02
v	Profit/(loss) from continuing operations before tax and exceptional items (III-IV)	1,817.00	1,220.30	59.89	3,728.20	1,113.71	2,514.88
		1,817.00	1,220.30		3,726.20	1,113.71	
	Exceptional items loss/ (gain) (net) (Refer note 6)	-	-	•	N.E.	115	150.40
VII	Profit/(loss) from continuing operations before tax (V-VI)	1,817.00	1,220.30	59.89	3,728.20	1,113.71	2,364.48
VIII	Tax expense						
	(a) Current tax (Refer note 7)	(725.20)	32.40	482.47	(352.10)	1,143.87	1,196.80
	(b) MAT credit entitlement	(313.00)	(170.30)	-	(568.10)	-	(3.90)
	(c) MAT credit entitlement written off	-	-		-		286.70
	(d) Deferred tax (Refer note 7)	1,298.10	(191.70)	(119.70)	1,093.40	(205.70)	(133.90)
	Total tax expenses	259.90	(329.60)	362.77	173.20	938.17	1,345.70
IX	Profit/(loss) from continuing operations after tax (VII-VIII)	1,557.10	1,549.90	(302.88)	3,555.00	175.54	1,018.78
x	Profit/(loss) from discontinued operations	-		-	-	1,054.70	1,054.70
	Gain on disposal of assets/settlement of liabilities attributable to the discontinued operations	-	-	-	-	1,745.50	41,009.50
	Tax expense of discontinued operations						
	(a) Current tax	-		362.73		362.73	362.73
	(b) MAT credit entitlement Profit/(loss) from discontinued operations after tax (Refer note 4a & 4b)		-	(202.72)	-		(362.73)
		-	-	(362.73)	-	2,437.47	42,064.20
	Profit/(loss) for the period (IX+X)	1,557.10	1,549.90	(665.61)	3,555.00	2,613.01	43,082.98
XII	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement gain/(loss) on defined benefits plans	3.20	27.20	(7.51)	25.40	(9.91)	82.50
	(b) Fair value gain / (loss) from investment in equity instruments (net)	911.30	1,608.50	(2,062.80)	(5,192.10)	(9,096.40)	(14,195.41)
	Items that may be reclassified to profit or loss						
	(a) Exchange differences on translation of foreign operations (net)	(1,113.97)	1,206.62	(144.38)	(43.91)	82.50	244.66
	(b) Exchange differences on net investment in foreign operations (net)	262.61	(989.34)	(439.31)	(371.22)	(292.15)	(3.61)
	Total other comprehensive income for the period	63.14	1,852.98	(2,654.00)	(5,581.83)	(9,315.96)	(13,871.86)
XIII	Total comprehensive income for the period (XI+XII)	1,620.24	3,402.88	(3,319.61)	(2,026.83)	(6,702.95)	29,211.12
	Profit for the period attributable to:						
	- Owners of the Company	1,302.50	1,523.10	(945.91)	3,153.60	2,201.71	42,156.58
	- Non-controlling interests	254.60	26.80	280.30	401.40	411.30	926.40
	Other comprehensive income for the period attributable to:	204.00	20.00	200.30	401.40	411.30	920.40
	- Owners of the Company	118.74	1,898.58	(2 604 80)	/5 A1C 12\	(0.355.35)	(12.054.90)
	- Non-controlling interests	(55.60)	(45.60)	(2,604.80)	(5,416.13)	(9,366.36)	(13,954.86)
	Total comprehensive income for the period attributable to:	(55.60)	(45.60)	(49.20)	(165.70)	50.40	83.00
	Owners of the Company	1,421,24	2 404 00	(0.550.74)	(0.000.50)		
	- Non-controlling interests		3,421.68	(3,550.71)	(2,262.53)	(7,164.65)	28,201.72
		199.00	(18.80)	231.10	235.70	461.70	1,009.40
	Earnings per equity share: (face value of Rs. 2 each) (not annualised)						
	-for continuing operations (1) Basic (in Rs.)				100	2.00	
	(2) Diluted (in Rs.)	0.54 0.53	0.63	(0.24)	1.30	(0.25)	(0.11)
	- for discontinued operations	0.53	0.63	(0.24)	1.29	(0.25)	(0.11)
	(1) Basic (in Rs.)		-	(0.15)		1.40	17.51
	(2) Diluted (in Rs.)			(0.15)	•	1.16	17.51
	- for continuing and discontinued operations			(0.15)	-	1.15	17.40
	(1) Basic (in Rs.)	0.51					
	(2) Diluted (in Rs.)	0.54	0.63	(0.39)	1.30	0.91	17.40
	See accompanying notes to the financial results	0.53	0.63	(0.39)	1.29	0.90	17.29
	oce accompanying notes to the infancial results						





- 1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 01 February 2019. The statutory auditors have carried limited review of the
- 2. The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

3. Information on Standalone Results:

(Rs in Lakhs)

Particulars	3 months ended 31-Dec-2018	Preceding 3 months ended 30-Sep-2018	Corresponding 3 months ended in the previous year 31-Dec-2017	Year to date figures for the current period ended 31-Dec-2018	Year to date figures for the previous period ended 31-Dec-2017	Previous year ended 31-Mar-2018
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Revenue from continuing operations	4,814.30	3,624.10	2,672.07	11,066.90	8,044.10	10,723.60
Profit/ (loss) before tax from continuing operations	86.60	271.30	170.43	619.80	236.70	66.30
Profit/ (loss) after tax from continuing operations	86.60	271.30	118.28	619.80	184.55	(220.37)
Profit/ (loss) after tax from discontinued operations			(362.73)	120	1,344.67	40,861.10
Total comprehensive income	999.60	1,892.20	(2,314.17)	(4,567.20)	(7,570.42)	26,408.03

4a. Pursuant to the Scheme of Arrangement (the 'Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT), Mumbai, vide Order dated 09 March 2018 (Order'), with effect from the Appointment Date i.e. 01 October 2017, the Human API business of the Company was transferred to Solara Active Pharma Sciences Limited ('Solara').

Pursuant to the above, Sequent Penems Private Limited has ceased to be the subsidiary of the Company.

In line with the approved Scheme, the comparative information in these results for the quarter and nine months ended 31 December 2017 have been revised from the published financial results for that quarter to exclude the results of Human API business and Sequent Penems Private Limited.

4b. During the previous year ended 31 March 2018, the Company completed the divestment of woman healthcare business (discontinued operations).

The results relating to discontinued business are as follows:

(Rs. in Lakhs)

Particulars	3 months ended 31-Dec-2018	Preceding 3 months ended 30-Sep-2018	Corresponding 3 months ended in the previous year 31-Dec-2017	Year to date figures for the current period ended 31-Dec-2018	Year to date figures for the previous period ended 31-Dec-2017	Previous year ended 31-Mar-2018
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total income			-		18,575.74	18,575.74
Total expenses	-	-	- 1		17,521.04	17,521.04
Profit/ (loss) before exceptional items and tax	-		-	-	1,054.70	1,054.70
Exceptional items			-			-
Profit/(loss) before tax	-		-		1,054.70	1,054.70
Gain on disposal of assats/settlement of liabilities attributable to the discontinued operations		-	¥ ()	-	1,745.50	41,009.50
Tax expense of discontinued operations			362.73		362.73	
Profit/ (loss) for the period			(362.73)	-	2,437.47	42,064.20

5. Post implementation of Goods and Services Tax (GST) with effect from 01 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period included excise duty which is now subsumed in GST. Revenue from operations for the year ended 31 March 2018 included excise duty up to 30 June 2017. Accordingly, revenue from operations for the nine months ended 31 December 2018 are not comparable with those of the previous periods presented.

6. Exceptional items:	(Rs in Lakhs)
Particulars	Previous year ended 31-Mar-2018
	AUDITED
- Write off of ineligible GST credits	116.10
- Goodwill impairment	790.00
- Contingent consideration reversal	(931.26)
- Liability towards pre-acquisition employee claims	175.56
Total	150.40

- 7. The tax expense for the quarter ended and nine months ended 31 December 2018 include:
 - Reversal of current taxes pertaining to earlier years of Rs. 1,321.80 lakhs and Rs. 1,639.00 lakhs respectively for subsidiaries on completion of tax assessments.
 Reversal of deferred tax asset of Rs. 971.60 lakhs and Rs. 971.60 lakhs respectively on completion of tax assessments.
- 8. During the period, the Company has revised the useful life of certain acquired intangible acquired from 5 years to 20 years. Had the useful life been 5 years, the impact on profit is as below: (Rs in Lakhs)

Particulars	3 months ended 31-Dec-2018	Preceding 3 months ended 30-Sep-2018	Year to date figures for the current period ended	
2)	UNAUDITED	UNAUDITED	31-Dec-2018 UNAUDITED	
Impect on profit	164.14	163.82	495.51	
NCI share on above	61.93	61.85	187.03	

- 9. With effect from C1 August 2018, the Company has acquired the EU-GMP API facility at Mahad, Maharashtra for a consideration of Rs. 4,640 lakhs. The Company is in the process of completing the Purchase Price Allocations of this acquisition and the business combination has been accounted based on provisional amounts as permitted under the Indian Accounting Standard 103 "Business Combinations"
- 10. 'Ind AS 115 Revenue from Contract with Customers', mandatory for reporting periods beginning on or after 01 April 2018, replaces existing revenue recognition requirement. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 01 April 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the unaudited financial results of the Company.
- 11. The previous period ligures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited

Manish Gupta Managing Director

Place: Thans

Date: 01 February 2019